Alloy Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $42M
Overview
A collaborative antibody discovery platform company providing transgenic animals and services to biopharma partners.
OncologyImmunologyInfectious Disease
Technology Platform
The ATX-Gx platform uses a suite of transgenic animals (mice, rats, rabbits) to generate fully human antibodies, combined with associated discovery services.
Funding History
1Total raised:$42M
Series C$42M
Opportunities
Potential to become a standard, industry-wide infrastructure provider as biologics discovery continues to grow.
Risk Factors
Revenue is dependent on the success and continued investment of partner companies in their external discovery programs.
Competitive Landscape
Competes with other transgenic animal platform companies like Ablexis (a Ligand company) and BioAtla, as well as in vitro display technologies.